CN116754756A - Methotrexate detection kit - Google Patents

Methotrexate detection kit Download PDF

Info

Publication number
CN116754756A
CN116754756A CN202310507880.0A CN202310507880A CN116754756A CN 116754756 A CN116754756 A CN 116754756A CN 202310507880 A CN202310507880 A CN 202310507880A CN 116754756 A CN116754756 A CN 116754756A
Authority
CN
China
Prior art keywords
methotrexate
buffer
glucose
reagent
phosphate dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310507880.0A
Other languages
Chinese (zh)
Inventor
龚俊
李微
张启飞
金石
刘希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Strong Biotechnologies Inc
Original Assignee
Beijing Strong Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Strong Biotechnologies Inc filed Critical Beijing Strong Biotechnologies Inc
Publication of CN116754756A publication Critical patent/CN116754756A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The application relates to a methotrexate detection kit. Specifically, the mutant glucose 6-phosphate dehydrogenase of the present application comprises one mutation or a combination thereof selected from the group consisting of: d306C, D375C, G426C. The detection kit prepared by using the glucose 6-phosphate dehydrogenase mutant has the advantages of strong specificity, high sensitivity, convenient operation, short detection time, accurate quantification and suitability for high-throughput detection.

Description

Methotrexate detection kit
The application is a divisional application of patent application No. 202010013644X of glucose-6-phosphate dehydrogenase mutant and application of the mutant in preparation of methotrexate detection reagent, which are filed on 1/7 th of 2020.
Technical Field
The application relates to the field of biological detection, in particular to mutant enzyme glucose 6-phosphate dehydrogenase (G6 PDH for short) and application thereof in a methotrexate detection kit.
Background
Hapten, some small molecule substances (molecular weight less than 4000 Da) alone are not able to induce an immune response, i.e. are not immunogenic, but are immunogenic when crosslinked or conjugated to a carrier such as a macromolecular protein or non-antigenic polylysine, inducing an immune response. These small molecule substances can bind to the response effect products, are antigenic, are only immunoreactive, are not immunogenic, and are also called incomplete antigens.
Hapten can bind to the corresponding antibody to generate antigen-antibody reaction, and antigen which can not independently excite human or animal body to generate antibody can not be generated. It is only immunoreactive, not immunogenic, also known as incomplete antigen. Most polysaccharides, lipids, hormones and small molecule drugs belong to the hapten group. If hapten is chemically bound to a protein molecule (carrier), new immunogenicity is obtained and the animal is stimulated to produce the corresponding antibody.
Small molecule antigens or haptens, which lack two or more sites available for sandwich methods, cannot be assayed by the double antibody sandwich method, and are often in competition mode. The principle is that the antigen in the specimen and a certain amount of enzyme-labeled antigen compete for binding with the solid phase antibody. The more the antigen content in the specimen, the less the enzyme-labeled antigen is bound on the solid phase, and the lighter the color development. ELISA assay for small molecule hormones, drugs and the like is commonly used.
Methotrexate (Methotrexate) has the following structural formula:
methotrexate is also known as aminomethylfolic acid, methotrexate, orange yellow crystalline powder, and has a melting point of 185-204 ℃ and is stable in air exposure at normal temperature, is easily dissolved in dilute alkali, acid or alkali metal carbonate solution, is slightly dissolved in dilute hydrochloric acid, and is almost insoluble in water, ethanol, chloroform and diethyl ether.
Methotrexate is antifolate antitumor drug, and can inhibit synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting growth and proliferation of tumor cells. The medicine is mainly used for treating chorionic epithelial cancer, malignant grape embryo, various acute leukemia, breast cancer, lung cancer, head and neck cancer, digestive tract cancer, cervical cancer, malignant lymphoma and the like. The arterial cannula is used for perfusion to treat head and neck cancer and liver cancer, and the biological agents such as methotrexate and adalimumab are used together, so that the disease symptoms of patients suffering from joint rheumatism can be effectively relieved, the progress of joint injury is slowed down, and the body functions can be improved. Can also be used for relieving hemorrhage by local embryo sac injection in ectopic pregnancy.
Methotrexate is a major therapeutic agent for leukemia, but in 1951 gudner et al proposed that aminopterin is effective for chronic RA, and is attracting attention as a therapeutic agent for RA, and is mainly used in europe and america. Methotrexate is a prescribed drug that must be prescribed by a physician and high doses can cause osteoporosis, joint pain, eye irritation, and diabetes, as well as may cause egg cell deficiency and oligospermia, hypofertility. Like other folic acid antagonists, methotrexate also has teratogenic effects and can cause stillbirth.
For the above reasons, methotrexate plasma concentration monitoring needs to be performed in time during the treatment process, and is an effective way for assisting clinical treatment, improving treatment effect and reducing toxicity risk.
The currently known methotrexate detection methods mainly comprise: high Performance Liquid Chromatography (HPLC), luminescence immunity, enzyme-linked immunosorbent assay (ELISA), etc. The high performance liquid chromatography can separate the drug from the metabolite and endogenous substances, has the characteristic of strong specificity, is a gold standard for detecting MTX plasma concentration, but the method requires a complex pretreatment process and long measurement time, and is not suitable for rapid detection of large samples. Immunological methods are affected by cross-reactions to some extent, but they have become the main method of therapeutic drug monitoring by virtue of their rapid and easy operation. The luminous immunoassay method has the disadvantages of high reagent cost, inapplicability to detection of conventional therapeutic drugs and inapplicability to large-scale popularization.
The prior art CN104569373a describes a methotrexate homogeneous enzyme immunoassay reagent and a preparation and detection method thereof, wherein the preparation method of the conjugate of glucose-6-phosphate dehydrogenase and methotrexate is disclosed:
a) Preparing a buffer solution, weighing 1.09g/L potassium dihydrogen phosphate, 1.70g/L disodium hydrogen phosphate and 8.5g/L sodium chloride, and regulating the pH to 7.4;
b) Weighing 3mg of glucose 6-phosphate dehydrogenase, and dissolving the glucose 6-phosphate dehydrogenase in 3mL of the solution obtained in the step a at room temperature to prepare a glucose 6-phosphate dehydrogenase solution;
c) 3mg of the methotrexate derivative was weighed and dissolved in 300. Mu.L of the solution obtained in the step a at room temperature to prepare a methotrexate derivative solution: methotrexate derivatives are shown below:
d) Mixing the solutions obtained in the steps b and c, and stirring at 2-8 ℃ for 1 hour to enable the glucose-6-phosphate dehydrogenase to be connected with the terminal carboxyl of the methotrexate;
e) And d, placing the mixed solution obtained in the step d into the solution obtained in the step a for dialysis and purification to obtain the glucose 6-phosphate dehydrogenase-methotrexate conjugate.
The prior art only indicates that the enzyme is connected with the terminal carboxyl of methotrexate, however, a plurality of groups (such as amino groups) which can be combined with the carboxyl exist on the enzyme, so that directional coupling is difficult to ensure, and the problems of low consistency of the obtained conjugate and large difference among kit batches still exist.
Disclosure of Invention
In view of the needs in the art, the present application provides a novel glucose 6-phosphate dehydrogenase mutant and its use in preparing a methotrexate detection kit.
According to some embodiments, a glucose 6-phosphate dehydrogenase mutant is provided. Unlike the glucose 6 phosphate dehydrogenase mutant of the prior published patent US006090567A (Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases), the glucose 6-phosphate dehydrogenase mutant of the present application comprises a mutation selected from the group consisting of: d306C, D375C, G426C.
According to some embodiments, there is provided a glucose 6-phosphate dehydrogenase mutant, the glucose 6-phosphate dehydrogenase mutant being represented by a sequence selected from the group consisting of: SEQ ID No.2, SEQ ID No.3, SEQ ID No.4.
According to some embodiments, a polynucleotide encoding a glucose 6-phosphate dehydrogenase mutant of the present application is provided.
According to some embodiments, there is provided an expression vector comprising a polynucleotide of the application.
According to some embodiments, there is provided a host cell comprising an expression vector of the application. The host cell may be prokaryotic (e.g., bacteria) or eukaryotic (e.g., yeast).
According to some embodiments, there is provided a conjugate which is a glucose 6-phosphate dehydrogenase mutant of the present application and a hapten in a molar ratio of 1:1 is coupled.
In some specific embodiments, the hapten has a molecular weight of 100Da to 4000Da, for example: 100. 150, 200, 250, 300, 350, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 520, 550, 570, 600, 620, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000.
According to the present application, the skilled person will understand that "hapten" also includes the form of its derivative. In order to facilitate the coupling with glucose-6-phosphate dehydrogenase, haptens (e.g.methotrexate) that do not themselves carry a coupling group (e.g.a group that reacts with a thiol group) may be engineered to carry a linker for covalent binding to the thiol group. Thus, in the present application, hapten derivatives refer to haptens engineered to bear a thiol-reactive group.
The hapten is selected from the group consisting of: small molecule drugs (e.g., antibiotics, psychotropic drugs), hormones, metabolites, sugars, lipids, and amino acids.
Hapten such as, but not limited to: vancomycin, theophylline, phenytoin, vitamin D, 25 hydroxy vitamin D, 1, 25 dihydroxyvitamin D, folic acid, cardiac glycoside (including digoxin, digitoxin), zymophenolic acid, lei Paming, cyclosporin A, methotrexate, amiodarone, methotrexate, tacrolimus, serum amino acids, bile acids, glycocholic acid, phenylalanine, ethanol, the metabolite cotinine of uronikotin, uromorphine, derivatives of uromonohydric phenol, neuropeptide tyrosine, plasma galanin, polyamines, histamine, thyrotropic hormone, prolactin, placental prolactin, growth hormone, follicle stimulating hormone, luteinizing hormone, adrenocorticotropic hormone, antidiuretic hormone, calcitonin, procalcitonin, parathyroid hormone, thyroxine, triiodothyronine, anti-triiodothyronine, free thyroxine, free triiodothyronine cortisol, urinary 17-hydroxycortic, urinary 17-ketosteroid, dehydroepiandrosterone and sulfate, aldosterone, urovanilloid, plasma renin, angiotensin, erythropoietin, testosterone, dihydrotestosterone, androstenedione, 17 alpha-hydroxyprogesterone, estrone, estriol, estradiol, progesterone, human chorionic gonadotropin, insulin, proinsulin, C peptide, gastrin, plasma prostaglandin, plasma 6-keto prostaglandin f1α, prostacyclin, epinephrine, catecholamine, norepinephrine, cholecystokinin, natriuretic acid, cyclic adenosine monophosphate, cyclic guanosine monophosphate, vasoactive peptides, somatostatin, secretin, substance P, neurotensin, thromboxane A2, thromboxane B2, 5 hydroxytryptamine, neuropeptides Y, osteocalcin.
In a specific embodiment, the hapten is methotrexate or a derivative thereof.
In a specific embodiment, the hapten is a methotrexate derivative with a sulfhydryl reactive group, such as, for example, a maleimide, bromoacetyl, vinyl sulfone, or aziridine.
In a specific embodiment, the hapten is a methotrexate derivative, as shown in formula I:
in some embodiments, m is an integer from 1 to 10, preferably an integer from 1 to 5, such as 1, 2, 3, 4, 5.
In a specific embodiment, the methotrexate derivative is represented by formula II:
according to some embodiments, there is provided an agent comprising a conjugate of the application.
According to some embodiments, there is provided the use of a glucose 6-phosphate dehydrogenase mutant of the application in the preparation of a methotrexate detection reagent.
According to some embodiments, there is provided the use of a conjugate of the application in the preparation of a methotrexate detection reagent.
In specific embodiments, the detection reagent is selected from the group consisting of: ELISA detection reagent, chemiluminescent detection reagent, homogeneous ELISA detection reagent and latex enhanced turbidimetry detection reagent.
In a specific embodiment, the detection reagent is preferably a reagent for competition-based detection.
According to some embodiments, there is provided the use of a conjugate of the application in the preparation of a methotrexate detection device.
In particular embodiments, the detection device may be prepared in the form of a well plate (e.g., 96-well plate), such as a plate coated with reagents according to the application.
In a specific embodiment, the detection device may be prepared in the form of particles (e.g. latex, magnetic beads), such as particles coated with the reagent according to the application.
According to some embodiments, there is provided a methotrexate detection kit comprising:
-a first agent comprising a substrate, a buffer and a methotrexate antibody; the substrate is a substrate for glucose-6-phosphate dehydrogenase;
-a second agent comprising a conjugate of the application and a buffer;
-optionally, a calibrator comprising 10mM to 500mM buffer, 0 μm to 2.0 μm methotrexate; and
-optionally, a quality control comprising 10mM to 500mM buffer, 0.2 μm to 2.0 μm methotrexate.
According to one embodiment, there is provided a methotrexate detection kit comprising:
a first reagent comprising:
10mM to 500mM buffer,
5mM to 50mM substrate,
0.05% to 0.5% w/v, preferably 0.2% to 0.5% w/v methotrexate antibody, 0.05% to 0.5% w/v, preferably 0.05% to 0.1% w/v stabilizer,
0.05% to 1% w/v, preferably 0.5% to 1% w/v sodium chloride,
0.05% to 0.5% w/v, preferably 0.05% to 0.1% w/v preservative;
a second reagent comprising:
10mM to 500mM buffer,
0.1% to 0.5% w/v of a conjugate according to the application,
0.05 to 0.5% w/v, preferably 0.05 to 0.1% w/v, of a stabilizer,
0.05% to 1% w/v, preferably 0.5% to 1% w/v sodium chloride,
0.05% to 0.5% w/v, preferably 0.05% to 0.1% w/v preservative;
in some embodiments, the buffer is selected from one or a combination of the following: TAPS, tromethamine buffer, phosphate buffer, tris-HCl buffer, citric acid-sodium citrate buffer, barbital buffer, glycine buffer, borate buffer, and trimethylol methane buffer; preferably, a phosphate buffer; the concentration of the buffer is 10mmol/L to 500mmol/L, preferably 50 to 200mM; the pH of the buffer is 7 to 8.4.
In some embodiments, the stabilizer is selected from one or a combination of the following: bovine serum albumin, trehalose, glycerol, sucrose, mannitol, glycine, arginine, polyethylene glycol 6000, polyethylene glycol 8000; bovine serum albumin is preferred.
In some embodiments, the preservative is selected from one or a combination of the following: azide, MIT, biological preservative PC (such as PC-300), merthiolate; the azide is selected from: sodium azide and lithium azide.
In some embodiments, the substrate comprises: glucose-6-phosphate, beta-nicotinamide adenine dinucleotide.
In some specific embodiments, the methotrexate antibody is derived from: rabbits, mice, rats, goats, sheep, cats, guinea pigs, dogs, primates, cows, horses, camelids, birds, humans.
In some specific embodiments, the methotrexate antibody is selected from the group consisting of: monoclonal antibodies, polyclonal antibodies, recombinant antibodies, chimeric antibodies, and antigen binding fragments.
According to some embodiments, there is provided a method of preparing a conjugate comprising the steps of:
1) Providing a methotrexate derivative according to the application, in particular in an aprotic solvent (e.g. but not limited to acetonitrile, dimethylformamide, dimethylsulfoxide);
2) Providing a glucose 6-phosphate dehydrogenase mutant, preferably in a buffer (which provides a reaction environment such as, but not limited to PBS, tris, TAPS, TAPSO, said buffer having a pH of 6.0 to 8.0);
3) Contacting the methotrexate derivative and the glucose 6-phosphate dehydrogenase mutant at a molar ratio n:1 for 1 hour to 4 hours (preferably 2 hours to 3 hours) at 18 ℃ to 28 ℃ such that the methotrexate derivative and the glucose 6-phosphate dehydrogenase mutant are coupled to obtain the seed conjugate;
4) The seed conjugate is optionally purified, e.g., desalted, etc., as desired.
In some embodiments, the contacting molar ratio of enzyme to hapten in the reaction system is 1: n, where n is 0.1 to 500, e.g., 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 100, 200, 300, 400, 500, and ranges between any of the foregoing values thereof. In a specific embodiment, the contacting molar ratio of enzyme to hapten in the reaction system is 5:1 to 1:5.
in some specific embodiments, steps 1) and 2) can be interchanged or in parallel.
In some specific embodiments, the glucose 6-phosphate dehydrogenase comprises one or more free sulfhydryl groups prior to coupling, thereby allowing for a directed reaction with methotrexate.
Wild-type glucose 6-phosphate dehydrogenase does not contain a free thiol group, and thus in some specific embodiments, the glucose 6-phosphate dehydrogenase is genetically engineered to have an amino acid mutation at a particular site (306, 375, or 426) to a cysteine, thereby carrying a free thiol group.
Drawings
FIG. 1G 6PDH (wild type) amino acid sequence (SEQ ID No. 1); is derived from Leuconostoc pseudoenteroides Leuconostoc pseudomesenteroides.
FIG. 2G 6PDH (D306C) amino acid sequence (SEQ ID No. 2).
FIG. 3G 6PDH (D375C) amino acid sequence (SEQ ID No. 3).
FIG. 4G 6PDH (G426C) amino acid sequence (SEQ ID No. 4).
Detailed Description
Examples
EXAMPLE 1 Synthesis of methotrexate derivatives
To a round bottom flask was added methotrexate (100 mg,0.22 mmol), dissolved in dry N, N-dimethylformamide (10 mL), 4-maleimidobutyric acid (39 mg,0.22 mmol) was added, triethylamine (44 mg,0.44 mmol) was added, and stirred under nitrogen until all dissolved.
HOAt (45 mg,0.33 mmol) was added to the reaction, stirred until all dissolved, HATU (125 mg,0.33 mmol) was added, stirred at room temperature (18-28 ℃ C., preferably 20-25 ℃ C.) for about 4h, and TLC detection. Purification by prep plate (MeOH/dcm=5:3) was performed directly after the reaction, and methotrexate derivative was finally obtained (45 mg, 35% yield).
The structure of the product was confirmed by a conventional method. This example provides methotrexate with a group that binds to enzymes.
EXAMPLE 2 coupling of methotrexate derivatives with G6PDH molecules
1. The coupling method of the application
The G6 PDH-methotrexate conjugate according to the application is coupled as follows: thiol-reactive groups (such as but not limited to maleimide groups) on methotrexate derivative molecules are covalently bound to thiol groups on G6PDH molecules.
1. The methotrexate derivative prepared in example 1 was dissolved in N, N-dimethylformamide (10 mM);
g6pdh solution: g6PDH (mutant of the application or mutant of the prior art) was dissolved in 0.2M phosphate buffer, pH8.0 (6.4 mM enzyme);
3. 200. Mu.l of glucose 6 phosphate dehydrogenase mutant solution was added to 750. Mu.l of buffer solution (0.05 mol/L Na) 2 HPO 4 、150mM NaCl、10mM EDTA、0.1％ NaN 3 Ph=7.2), 50 μl of methotrexate derivative solution is added;
4. the above mixed solution was subjected to desalting treatment by shaking at room temperature (18-28deg.C, preferably 20-25deg.C) for 2-3 hours, and the resultant product was G6 PDH-methotrexate conjugate (concentration 0.1mM-2.0 mM).
2. Control coupling method A
G6 PDH-methotrexate conjugate was prepared according to the method disclosed in example four of CN 104569373A.
3. Control coupling method B (relying on activation of the self-contained group of methotrexate)
1. 2.38mL of glucose hexaphosphate dehydrogenase was dissolved in 12mL of Tris buffer, followed by sequential addition of 225mg of reduced nicotinamide adenine dinucleotide NADH,135mg of glucose-6-phosphate, and 2.25mL of dimethyl sulfoxide; the pH value of the Tris buffer solution is 9.0, and the concentration of each component is as follows: 0.05mol/L Tris, 3.3mM magnesium chloride, 145.4mM sodium chloride.
2. Activation of methotrexate derivatives: 10mg of methotrexate derivative is dissolved in 420. Mu.L of dimethyl sulfoxide and 180. Mu.L of dimethylformamide, 6. Mu.L of tributyl amine and 350. Mu.L of isobutyl chloroformate are added and stirred at 2-8 ℃ for 30 minutes;
3. mixing the solutions obtained in the steps 1 and 2, stirring for 12-16 hours at the temperature of 2-8 ℃, and purifying the coupled enzyme-labeled antigen by using a G-25 gel chromatographic column to obtain the glucose-6-phosphate dehydrogenase labeled methotrexate derivative.
EXAMPLE 3 preparation of the kit
The following kits for the detection of methotrexate were prepared, comprising:
1. preparation of the first reagent:
2. preparation of the second reagent:
3. calibration material: 20mM HEPES buffer, 0.2-0.8. Mu.M, 0.9-1.2. Mu.M, 1.3-2.0. Mu.M methotrexate (or added as needed);
4. quality control product: 20mM HEPES buffer, 0. Mu.M, 0.13. Mu.M, 0.25. Mu.M, 0.50. Mu.M, 1.00. Mu.M, 2.00. Mu.M methotrexate (or added as needed).
5. The above reagents (optionally including quality control substances and calibration materials) are assembled into a detection kit.
Test case
In a homogeneous reaction system, methotrexate and G6 PDH-methotrexate conjugate in a sample compete for binding to the anti-methotrexate antibody site simultaneously, and as the enzyme activity decreases after the antibody is bound with the conjugate, the more methotrexate in the sample is free, the more the antibody site competing for binding is, the less the antibody is bound with the enzyme conjugate, and the enzyme conjugate which is not bound with the antibody catalyzes the oxidation form (NAD + ) Converted into beta-nicotinamide adenine dinucleotide reduction (NADH), the concentration of the methotrexate in the sample is directly proportional to the generation amount of NADH, and the concentration of the methotrexate in the sample can be obtained through the change of absorbance.
TABLE 1 full automatic Biochemical instrument parameters
Test example 1. Performance of the kit of the application
1. Scaling absorbance
Methotrexate calibrator was dissolved in buffer (0.9% NaCl,0.1% NaN) 3 ) 6 concentrations of calibrator were prepared. The calibration working volume is 2-10 mu L, then 100-200 mu L of the first reagent and 50-100 mu L of the second reagent are added, the absorbance change rate of a specific reading point is measured by a velocity method, the dominant wavelength is 340nm, the auxiliary wavelength is 405nm, and a calibration curve is drawn. The establishment and optimization of the calibration curve in the application are completed on Hitachi 7180, but other mainstream models (AU 680, attapulgite C16000, etc.) are available through detection.
2. Precision experiments
And (3) measuring high, medium and low quality control products and clinical samples by using the calibration curve established above.
TABLE 2 precision of
3. Linearity of
TABLE 3 linearities
4. Airborne stability (D375C mutant)
Selecting quality control products with high, medium and low concentrations, detecting for three times every day or every other day, and data show that the calibration period of the kit can be stabilized for more than two weeks; the reagents were placed on the machine after unsealing, the test showed on-board stability for more than 40 days, and the data are presented in table 6 (where 40 days represents the test data after 40 days of on-board recalibration).
5. Drug interference experiment
The 20 compounds and drugs commonly used are selected, and the compound with the concentration of methotrexate of 10 mu M has no obvious interference on the detection (D375C mutant) of the kit.
TABLE 4 drug interference experiment
Detection example 2 inhibition of antibodies in conjugates
1. Principle of detection of antibody inhibition
When the antibody is combined with the G6 PDH-methotrexate conjugate, the activity of the G6PDH enzyme is influenced due to steric hindrance, so that the efficiency of catalyzing NAD to be converted into NADH is reduced, and the difference between an added antibody and an experimental group without the added antibody is compared by detecting the change of the NADH amount, wherein the difference is expressed as the inhibition capability of the antibody on the G6 PDH.
2. Reaction system
TABLE 5 preparation of reagents for detection of antibody inhibition
3. Results
And comparing the absorbance measurement value of the G6 PDH-methotrexate conjugate when the antibody is added with the antibody is not added with the antibody, and obtaining the inhibition condition of the antibody on the G6 PDH.
Compared with the conjugate prepared by the published mutation site (A45C, K C), the enzyme mutant of the application has obviously improved antibody inhibition rate, and can reach more than 44.6% (G426C: 44.6%; D375C: 51%), up to 60.3% (D306C). Whereas the inhibition rate of the previously published mutation site (e.g. a45C, K55C) is 39.7% to 42.2%.
While not being limited to a particular theory, it may be explained in part as: in comparison with the G6PDH mutant (A45C, K C) in the prior art, the mutation site (i.e. the site for introducing free sulfhydryl) in the enzyme mutant is the coupling site with hapten (such as hormone, small molecule drug, etc.). When hapten is combined with hapten specific antibody at this position, the steric hindrance formed has a great influence on the activity of G6PDH enzyme, and after mutation is introduced, the steric folding of the molecule cannot be substantially influenced. Therefore, the position of this mutation site is very important, and it is necessary to combine the activity of the G6PDH enzyme, the spatial folding of the coupling molecule, and the sufficient exposure of the hapten epitope.
The mutant of the enzyme has obvious improvement on the inhibition rate of the antibody. After the conjugate of the enzyme mutant and methotrexate is prepared into a kit, the reagent has obvious performance improvement in the aspects of the inter-batch variation coefficient, linearity, specificity and the like.

Claims (3)

1. A methotrexate detection kit comprising:
a first agent comprising a substrate, an anti-methotrexate antibody, and a buffer;
a second reagent comprising a conjugate, a buffer;
optionally, a calibrator comprising 10mM to 500mM buffer, 0 μm to 2.0 μm methotrexate; and
optionally, a quality control comprising 10mM to 500mM buffer, 0.2 μm to 2.0 μm methotrexate;
the conjugate is prepared from a glucose 6-phosphate dehydrogenase mutant and a methotrexate derivative according to a molar ratio of 1:1, covalent coupling;
the methotrexate derivative is represented by formula I:
wherein,,
m is an integer from 1 to 10, preferably an integer from 1 to 5;
preferably, the methotrexate derivative is of formula II:
the glucose 6-phosphate dehydrogenase mutant comprises a D306C mutation compared to the wild-type glucose 6-phosphate dehydrogenase; the glucose 6-phosphate dehydrogenase mutant is shown in SEQ ID No. 2.
2. The methotrexate detection kit according to claim 1, comprising:
a first reagent comprising:
10mM to 500mM, preferably 50mM to 200mM, buffer,
5mM to 50mM, preferably 10mM to 20mM, glucose-6-phosphate,
5mM to 50mM, preferably 10mM to 20mM, oxidized beta-nicotinamide adenine dinucleotide,
0.05% to 0.5% w/v, preferably 0.2% to 0.5% w/v, of methotrexate antibody,
0.05 to 0.5% w/v, preferably 0.05 to 0.1% w/v, of a stabilizer,
0.05% to 1% w/v, preferably 0.5% to 1% w/v sodium chloride,
0.05% to 0.5% w/v, preferably 0.05% to 0.1% w/v preservative;
a second reagent comprising:
10mM to 500mM, preferably 50mM to 200mM, buffer,
0.05% to 0.5% w/v, preferably 0.1% to 0.5% w/v of said conjugate,
0.05 to 0.5% w/v, preferably 0.05 to 0.1% w/v, of a stabilizer,
0.05% to 1% w/v, preferably 0.5% to 1% w/v sodium chloride,
0.05% to 0.5% w/v, preferably 0.05% to 0.1% w/v preservative;
the buffer is selected from one or a combination of the following: TAPS buffer, phosphate buffer, glycine buffer, tris buffer, boric acid buffer, MOPS buffer, HEPES buffer;
the pH of the buffer is 7 to 8.4;
the stabilizer is selected from one or a combination of the following: bovine serum albumin, trehalose, glycerol, sucrose, mannitol, glycine, arginine, polyethylene glycol 6000, polyethylene glycol 8000; bovine serum albumin is preferred;
the preservative is selected from one or a combination of the following: azide, MIT, bio-preservative PC, merthiolate;
preferably, the preservative is selected from: sodium azide, lithium azide, PC-300.
3. The methotrexate detection kit according to claim 2, comprising:
a first reagent comprising:
tris buffer 55mM, PH8.0,
10mM glucose-6-phosphate,
10mM oxidized beta-nicotinamide adenine dinucleotide, 0.2% w/v methotrexate antibody,
0.1% w/v bovine serum albumin,
0.85％w/v NaCl、
0.05% w/v sodium azide;
a second reagent comprising:
120mM Tris buffer, pH8.2,
0.1% w/v of the conjugate,
0.1% w/v bovine serum albumin,
0.85％w/v NaCl、
0.05% w/v sodium azide.
CN202310507880.0A 2019-01-09 2020-01-07 Methotrexate detection kit Pending CN116754756A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910017764 2019-01-09
CN2019100177644 2019-01-09
CN201910423122.4A CN110174363A (en) 2019-01-09 2019-05-21 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN2019104231224 2019-05-21
CN202010013644.XA CN111487208B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of methotrexate detection reagent

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202010013644.XA Division CN111487208B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of methotrexate detection reagent

Publications (1)

Publication Number Publication Date
CN116754756A true CN116754756A (en) 2023-09-15

Family

ID=67691613

Family Applications (52)

Application Number Title Priority Date Filing Date
CN201910423122.4A Pending CN110174363A (en) 2019-01-09 2019-05-21 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN201911365439.3A Active CN111239060B (en) 2019-01-09 2019-12-26 6-phosphoglucose dehydrogenase mutant and application thereof in preparing theophylline detection reagent
CN202310257027.8A Active CN116144619B (en) 2019-01-09 2019-12-26 Theophylline Detection Kit
CN202310217235.5A Pending CN116359146A (en) 2019-01-09 2019-12-26 Method for preparing conjugate
CN202310811498.9A Pending CN116698772A (en) 2019-01-09 2019-12-27 Method for preparing conjugate
CN202211151264.8A Pending CN116008201A (en) 2019-01-09 2019-12-27 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of detection reagent
CN202211151405.6A Active CN115791649B (en) 2019-01-09 2019-12-27 Glycocholic acid detection kit
CN202211153004.4A Pending CN115808398A (en) 2019-01-09 2019-12-27 Method for preparing conjugate
CN201911372147.2A Active CN112285037B (en) 2019-01-09 2019-12-27 6-phosphoglucose dehydrogenase mutant and application thereof in preparing detection reagent
CN202310811210.8A Pending CN116626281A (en) 2019-01-09 2019-12-27 Digitoxin detection kit
CN201911372535.0A Active CN112285038B (en) 2019-01-09 2019-12-27 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of digitoxin detection reagent
CN202310811212.7A Pending CN116735512A (en) 2019-01-09 2019-12-27 Use of conjugates in the preparation of detection reagents
CN201911404154.6A Active CN111504920B (en) 2019-01-09 2019-12-31 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of cortisol detection reagent
CN202310365160.5A Pending CN116355873A (en) 2019-01-09 2019-12-31 Preparation method of conjugate
CN202310724066.4A Pending CN116773827A (en) 2019-01-09 2019-12-31 Use of conjugates in the preparation of detection reagents
CN201911403882.5A Active CN111650135B (en) 2019-01-09 2019-12-31 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of phenytoin detection reagent
CN202310726493.6A Pending CN116773795A (en) 2019-01-09 2019-12-31 Preparation method of conjugate
CN202310364266.3A Pending CN116718764A (en) 2019-01-09 2019-12-31 Use of conjugate in preparation of phenytoin detection reagent
CN202310364997.8A Pending CN116298257A (en) 2019-01-09 2019-12-31 Phenytoin detection kit
CN202310726498.9A Pending CN116559472A (en) 2019-01-09 2019-12-31 Cortisol detection kit
CN202311025752.9A Pending CN117074335A (en) 2019-01-09 2020-01-02 Use of conjugates in the preparation of detection reagents
CN202311025762.2A Pending CN117054643A (en) 2019-01-09 2020-01-02 Vancomycin detection kit
CN202311025756.7A Pending CN117030640A (en) 2019-01-09 2020-01-02 Method for preparing conjugate
CN202010000321.7A Active CN111487206B (en) 2019-01-09 2020-01-02 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of vancomycin detection reagent
CN202310810479.4A Pending CN116819060A (en) 2019-01-09 2020-01-03 Digoxin detection kit
CN202310810455.9A Pending CN116840467A (en) 2019-01-09 2020-01-03 Method for preparing conjugate
CN202010004879.2A Active CN111487207B (en) 2019-01-09 2020-01-03 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of digoxin detection reagent
CN202310811497.4A Pending CN116840468A (en) 2019-01-09 2020-01-03 Use of conjugates in the preparation of detection reagents
CN202310452740.8A Pending CN116430056A (en) 2019-01-09 2020-01-06 Method for preparing conjugate
CN202310452946.0A Pending CN116559425A (en) 2019-01-09 2020-01-06 Use of conjugates in the preparation of detection reagents
CN202310320137.4A Pending CN116148198A (en) 2019-01-09 2020-01-06 Preparation method of gentamicin detection reagent
CN202010009570.2A Active CN111537451B (en) 2019-01-09 2020-01-06 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of tacrolimus detection reagent
CN202310320729.6A Pending CN116297271A (en) 2019-01-09 2020-01-06 Use of conjugates in the preparation of kits
CN202010009771.2A Active CN111504921B (en) 2019-01-09 2020-01-06 6-glucose phosphate dehydrogenase mutant and application thereof in preparation of gentamicin detection reagent
CN202310453290.4A Pending CN116338215A (en) 2019-01-09 2020-01-06 Tacrolimus detection kit
CN202310318754.0A Pending CN116124721A (en) 2019-01-09 2020-01-06 Gentamicin detection kit
CN202310554774.8A Pending CN116679047A (en) 2019-01-09 2020-01-07 Method for preparing conjugate
CN202310553479.0A Pending CN116699125A (en) 2019-01-09 2020-01-07 Use of conjugates in the preparation of detection reagents
CN202310508418.2A Pending CN116381253A (en) 2019-01-09 2020-01-07 Method for preparing conjugate
CN202010013174.7A Active CN111678874B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of cyclosporine A detection reagent
CN202010013644.XA Active CN111487208B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of methotrexate detection reagent
CN202310508217.2A Pending CN116298330A (en) 2019-01-09 2020-01-07 Use of conjugates in the preparation of detection reagents
CN202310507880.0A Pending CN116754756A (en) 2019-01-09 2020-01-07 Methotrexate detection kit
CN202310555230.3A Pending CN116718761A (en) 2019-01-09 2020-01-07 Cyclosporine A detection kit
CN202310702858.1A Pending CN116859035A (en) 2019-01-09 2020-01-08 Use of conjugates in the preparation of detection reagents
CN202010017376.9A Active CN111537452B (en) 2019-01-09 2020-01-08 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of amikacin detection reagent
CN202310726230.5A Pending CN116577495A (en) 2019-01-09 2020-01-08 Method for preparing conjugate
CN202310702860.9A Pending CN116699122A (en) 2019-01-09 2020-01-08 Rapamycin detection kit
CN202310725902.0A Pending CN116577494A (en) 2019-01-09 2020-01-08 Use of conjugates in the preparation of detection reagents
CN202310702870.2A Pending CN116840462A (en) 2019-01-09 2020-01-08 Method for preparing conjugate
CN202310726069.1A Pending CN116754761A (en) 2019-01-09 2020-01-08 Amikacin detection kit
CN202010016535.3A Active CN111693473B (en) 2019-01-09 2020-01-08 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of rapamycin detection reagent

Family Applications Before (42)

Application Number Title Priority Date Filing Date
CN201910423122.4A Pending CN110174363A (en) 2019-01-09 2019-05-21 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN201911365439.3A Active CN111239060B (en) 2019-01-09 2019-12-26 6-phosphoglucose dehydrogenase mutant and application thereof in preparing theophylline detection reagent
CN202310257027.8A Active CN116144619B (en) 2019-01-09 2019-12-26 Theophylline Detection Kit
CN202310217235.5A Pending CN116359146A (en) 2019-01-09 2019-12-26 Method for preparing conjugate
CN202310811498.9A Pending CN116698772A (en) 2019-01-09 2019-12-27 Method for preparing conjugate
CN202211151264.8A Pending CN116008201A (en) 2019-01-09 2019-12-27 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of detection reagent
CN202211151405.6A Active CN115791649B (en) 2019-01-09 2019-12-27 Glycocholic acid detection kit
CN202211153004.4A Pending CN115808398A (en) 2019-01-09 2019-12-27 Method for preparing conjugate
CN201911372147.2A Active CN112285037B (en) 2019-01-09 2019-12-27 6-phosphoglucose dehydrogenase mutant and application thereof in preparing detection reagent
CN202310811210.8A Pending CN116626281A (en) 2019-01-09 2019-12-27 Digitoxin detection kit
CN201911372535.0A Active CN112285038B (en) 2019-01-09 2019-12-27 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of digitoxin detection reagent
CN202310811212.7A Pending CN116735512A (en) 2019-01-09 2019-12-27 Use of conjugates in the preparation of detection reagents
CN201911404154.6A Active CN111504920B (en) 2019-01-09 2019-12-31 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of cortisol detection reagent
CN202310365160.5A Pending CN116355873A (en) 2019-01-09 2019-12-31 Preparation method of conjugate
CN202310724066.4A Pending CN116773827A (en) 2019-01-09 2019-12-31 Use of conjugates in the preparation of detection reagents
CN201911403882.5A Active CN111650135B (en) 2019-01-09 2019-12-31 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of phenytoin detection reagent
CN202310726493.6A Pending CN116773795A (en) 2019-01-09 2019-12-31 Preparation method of conjugate
CN202310364266.3A Pending CN116718764A (en) 2019-01-09 2019-12-31 Use of conjugate in preparation of phenytoin detection reagent
CN202310364997.8A Pending CN116298257A (en) 2019-01-09 2019-12-31 Phenytoin detection kit
CN202310726498.9A Pending CN116559472A (en) 2019-01-09 2019-12-31 Cortisol detection kit
CN202311025752.9A Pending CN117074335A (en) 2019-01-09 2020-01-02 Use of conjugates in the preparation of detection reagents
CN202311025762.2A Pending CN117054643A (en) 2019-01-09 2020-01-02 Vancomycin detection kit
CN202311025756.7A Pending CN117030640A (en) 2019-01-09 2020-01-02 Method for preparing conjugate
CN202010000321.7A Active CN111487206B (en) 2019-01-09 2020-01-02 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of vancomycin detection reagent
CN202310810479.4A Pending CN116819060A (en) 2019-01-09 2020-01-03 Digoxin detection kit
CN202310810455.9A Pending CN116840467A (en) 2019-01-09 2020-01-03 Method for preparing conjugate
CN202010004879.2A Active CN111487207B (en) 2019-01-09 2020-01-03 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of digoxin detection reagent
CN202310811497.4A Pending CN116840468A (en) 2019-01-09 2020-01-03 Use of conjugates in the preparation of detection reagents
CN202310452740.8A Pending CN116430056A (en) 2019-01-09 2020-01-06 Method for preparing conjugate
CN202310452946.0A Pending CN116559425A (en) 2019-01-09 2020-01-06 Use of conjugates in the preparation of detection reagents
CN202310320137.4A Pending CN116148198A (en) 2019-01-09 2020-01-06 Preparation method of gentamicin detection reagent
CN202010009570.2A Active CN111537451B (en) 2019-01-09 2020-01-06 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of tacrolimus detection reagent
CN202310320729.6A Pending CN116297271A (en) 2019-01-09 2020-01-06 Use of conjugates in the preparation of kits
CN202010009771.2A Active CN111504921B (en) 2019-01-09 2020-01-06 6-glucose phosphate dehydrogenase mutant and application thereof in preparation of gentamicin detection reagent
CN202310453290.4A Pending CN116338215A (en) 2019-01-09 2020-01-06 Tacrolimus detection kit
CN202310318754.0A Pending CN116124721A (en) 2019-01-09 2020-01-06 Gentamicin detection kit
CN202310554774.8A Pending CN116679047A (en) 2019-01-09 2020-01-07 Method for preparing conjugate
CN202310553479.0A Pending CN116699125A (en) 2019-01-09 2020-01-07 Use of conjugates in the preparation of detection reagents
CN202310508418.2A Pending CN116381253A (en) 2019-01-09 2020-01-07 Method for preparing conjugate
CN202010013174.7A Active CN111678874B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of cyclosporine A detection reagent
CN202010013644.XA Active CN111487208B (en) 2019-01-09 2020-01-07 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of methotrexate detection reagent
CN202310508217.2A Pending CN116298330A (en) 2019-01-09 2020-01-07 Use of conjugates in the preparation of detection reagents

Family Applications After (9)

Application Number Title Priority Date Filing Date
CN202310555230.3A Pending CN116718761A (en) 2019-01-09 2020-01-07 Cyclosporine A detection kit
CN202310702858.1A Pending CN116859035A (en) 2019-01-09 2020-01-08 Use of conjugates in the preparation of detection reagents
CN202010017376.9A Active CN111537452B (en) 2019-01-09 2020-01-08 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of amikacin detection reagent
CN202310726230.5A Pending CN116577495A (en) 2019-01-09 2020-01-08 Method for preparing conjugate
CN202310702860.9A Pending CN116699122A (en) 2019-01-09 2020-01-08 Rapamycin detection kit
CN202310725902.0A Pending CN116577494A (en) 2019-01-09 2020-01-08 Use of conjugates in the preparation of detection reagents
CN202310702870.2A Pending CN116840462A (en) 2019-01-09 2020-01-08 Method for preparing conjugate
CN202310726069.1A Pending CN116754761A (en) 2019-01-09 2020-01-08 Amikacin detection kit
CN202010016535.3A Active CN111693473B (en) 2019-01-09 2020-01-08 Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of rapamycin detection reagent

Country Status (1)

Country Link
CN (52) CN110174363A (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110174363A (en) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN113046335B (en) * 2019-12-27 2023-05-26 中国科学院天津工业生物技术研究所 Bionic coenzyme-favored glucose 6-phosphate dehydrogenase mutant and application thereof
CN115856278B (en) * 2020-01-07 2024-06-04 北京九强生物技术股份有限公司 Tobramycin detection kit
CN112114127A (en) * 2020-09-09 2020-12-22 武汉生之源生物科技股份有限公司 Glycocholic acid homogeneous enzyme immunoassay kit and preparation method and application thereof
CN112225795A (en) * 2020-10-14 2021-01-15 湖南苏阳医疗科技有限公司 6-hydroxy sulfate melatonin derivative and preparation method and application of immunogen and specific antibody thereof
CN112574969A (en) * 2020-12-28 2021-03-30 郑州伊美诺生物技术有限公司 G6PDH mutant and application thereof
CN113567662A (en) * 2021-07-08 2021-10-29 重庆中元汇吉生物技术有限公司 Kit for determining glycocholic acid and preparation method thereof
CN113736744B (en) * 2021-10-14 2023-07-18 江南大学 Digitoxin monoclonal antibody hybridoma cell strain and application thereof
CN115236216B (en) * 2022-06-07 2024-03-01 合肥和合医疗科技有限公司 Kit for detecting immunosuppressant in whole blood by high performance liquid chromatography tandem mass spectrometry, preparation method and detection method thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116301B1 (en) * 1970-12-07 1974-08-30 Brun Lab Sa Le
US4190496A (en) * 1971-05-14 1980-02-26 Syva Company Homogeneous enzyme assay for antibodies
US3997525A (en) * 1974-01-16 1976-12-14 Bio-Tec, Inc. Tetra-125 iodo-di-tyramine of digitalis derivative and process for making the same
DE2901218A1 (en) * 1979-01-13 1980-07-17 Byk Gulden Lomberg Chem Fab THEOPHYLLIN
JPS5618983A (en) * 1979-07-25 1981-02-23 Eisai Co Ltd Theophylline derivative and its preapration
US4262089A (en) * 1980-04-07 1981-04-14 Syva Company Theophylline antigens and antibodies
US4341866A (en) * 1980-06-02 1982-07-27 Syva Company Antienzyme termination in enzyme immunoassays
JPS57178159A (en) * 1981-04-27 1982-11-02 Banyu Pharmaceut Co Ltd Chemical reagent for detection of amicacin and its determination
US4608336A (en) * 1981-08-27 1986-08-26 Miles Laboratories, Inc. #3B theophylline immunoassay employing 9-theophylline reagents
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
EP0119767B1 (en) * 1983-03-11 1990-11-22 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Method of measuring ligands
IT1199088B (en) * 1984-03-09 1988-12-30 Miles Italiana SPECIFIC BOND TEST BY USING ANTI-G6PDH AS A MARKER
US4622294A (en) * 1985-02-08 1986-11-11 Kung Viola T Liposome immunoassay reagent and method
US5068198A (en) * 1986-03-26 1991-11-26 Syntex (U.S.A.) Inc. Liquid single reagent for assays involving confining gels
EP0399127A1 (en) * 1989-05-23 1990-11-28 Pharmacia ENI Diagnostics Inc. Homogeneous immunochemical method for determining haptens by means of ion selective electrodes
DE3919915A1 (en) * 1989-06-19 1990-12-20 Boehringer Mannheim Gmbh AMINOALKYLMALEIMIDES AND DERIVED HAPTEN AND ANTIGEN DERIVATIVES AND CONJUGATES WITH PEPTIDES OR PROTEINS
JPH0833394B2 (en) * 1990-10-03 1996-03-29 三洋化成工業株式会社 Method for producing enzyme-labeled hapten
DE69133095T2 (en) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporine immunoassay
CA2055812A1 (en) * 1990-11-20 1992-05-21 Carl N. Skold Method of stabilizing enzyme conjugates
CA2087397A1 (en) * 1992-01-22 1993-07-23 Kazuhisa Kubotsu Immunoassay and reagents used therefor
CA2156397C (en) * 1993-04-08 2007-05-15 Valerie Quesniaux Rapamycin assay
US6455288B1 (en) * 1993-04-08 2002-09-24 Dade Behring Marburg Gmbh Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US5747352A (en) * 1994-05-23 1998-05-05 Beckman Instruments, Inc. Reagents and methods for the rapid and quantitative assay of pharmacological agents
WO2000022000A1 (en) * 1998-10-09 2000-04-20 Isotechnika, Inc. Methods for the production of antibodies to specific regions of cyclosporine and cyclosporine metabolites
AUPP751398A0 (en) * 1998-12-04 1999-01-07 Commonwealth Scientific And Industrial Research Organisation Methotrexate derivatives
JP4352286B2 (en) * 1999-07-28 2009-10-28 東洋紡績株式会社 Mutant glucose-6-phosphate dehydrogenase and method for producing the same
US7078495B1 (en) * 1999-08-03 2006-07-18 Dade Behring Inc. Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
US6653456B2 (en) * 2001-07-31 2003-11-25 Roche Diagnostics Corporation Site-specific aminoglycoside derivatives and their use in immunodiagnostic assays
US20050176080A1 (en) * 2004-02-10 2005-08-11 Vani Bodepudi Hapten, immunogens and derivatives of ascomycin useful for preparation of antibodies and immunoassays
US20060046273A1 (en) * 2004-08-27 2006-03-02 Lin-Zhi International Inc. Homogeneous enzyme immunoassay for oral fluid
MX2007007262A (en) * 2004-12-17 2007-10-19 Isotechnika Inc Metabolites of cyclosporin analogs.
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
JP4746926B2 (en) * 2005-06-29 2011-08-10 シスメックス株式会社 Glucose-6-phosphate dehydrogenase-containing reagent and glucose-6-phosphate dehydrogenase stabilization method
HUE058030T2 (en) * 2007-04-11 2022-06-28 Biomarin Pharm Inc Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
CN101638640B (en) * 2009-09-07 2011-01-12 北京利德曼生化股份有限公司 Glucose-6-phosphoric acid dehydrogenase and nucleotide sequence, recombinant vector, recombinant host cell and kit thereof
US20130280745A1 (en) * 2010-11-24 2013-10-24 Dh Technologies Development Pte. Ltd. High-throughput, sensitive detection of glucose-6-phosphate dehydrogenase
CA2818169A1 (en) * 2010-11-24 2012-05-31 Dh Technologies Development Pte. Ltd. High-throughput, sensitive detection of glucose-6-phosphate dehydrogenase
CN102565399B (en) * 2010-12-07 2015-06-03 北京望尔生物技术有限公司 Method for detecting hydrocortisone and special enzyme-linked immunosorbent assay kit thereof
CN102807618A (en) * 2011-08-10 2012-12-05 重庆金域医学检验所有限公司 Preparation method of phenytoin homogeneous enzyme immunoassay kit and phenytoin polyclonal antibodies
JP5896375B2 (en) * 2011-09-09 2016-03-30 池田食研株式会社 Modified glucose dehydrogenase gene
CN102424829B (en) * 2011-10-26 2013-10-16 苏州汉酶生物技术有限公司 Method for synthesizing temsirolimus through enzyme catalysis
US8771964B2 (en) * 2012-02-02 2014-07-08 Siemens Healthcare Diagnostics Inc. Compositions and methods for detection of methadone metabolite
AU2013274078A1 (en) * 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CN103242446A (en) * 2012-07-25 2013-08-14 苏州博源医疗科技有限公司 Theophylline immunogen and preparation method and application thereof
CN102757391B (en) * 2012-08-01 2015-08-26 苏州博源医疗科技有限公司 A kind of Phenobarbital derivatives and its preparation method and application
ES2911268T3 (en) * 2013-12-17 2022-05-18 Siemens Healthcare Diagnostics Inc Preparation of multi-hapten mutant G6PDH conjugates and their use for detection of multiple analytes
CN104016923B (en) * 2014-01-08 2016-08-31 南开大学 Phenytoin derivant and its production and use
CN103760348B (en) * 2014-02-11 2015-03-11 苏州博源医疗科技有限公司 Glycocholic acid immunodetection reagent and preparing method and detecting method thereof
CN103739703B (en) * 2014-02-11 2015-07-15 苏州博源医疗科技有限公司 Glycocholic acid immunogen, anti-glycocholic acid specific antibody and detection reagent
JP6398295B2 (en) * 2014-04-30 2018-10-03 ニプロ株式会社 Mutant glucose-6-phosphate dehydrogenase
CN104447745B (en) * 2014-11-06 2016-03-30 济南金域医学检验中心有限公司 A kind of theophylline homogeneous enzyme immunoassay detects tests test kit and preparation method thereof
CN104569373B (en) * 2015-01-27 2016-08-17 苏州博源医疗科技有限公司 A kind of methotrexate homogeneous enzyme immunoassay detectable and preparation thereof and detection method
JP2018512597A (en) * 2015-02-04 2018-05-17 ジェネンテック， インコーポレイテッド Mutant smoothened and method of using the same
CN105131105A (en) * 2015-07-27 2015-12-09 苏州博源医疗科技有限公司 Cortisol immunogen, derivative, antibody, detection reagent and preparation method
CN105132521A (en) * 2015-09-14 2015-12-09 绍兴圣康生物科技有限公司 Glycocholic acid testing kit and use method of glycocholic acid testing kit
CN106405069A (en) * 2016-04-06 2017-02-15 李松羊 Preparation method for homogeneous enzyme immunodiagnosis reagent used for glycocholic acid
CN105802927B (en) * 2016-04-08 2019-07-26 暨南大学 A kind of glucose-6-phosphate dehydrogenase and its encoding gene and application
CN106565809B (en) * 2016-07-08 2018-05-01 北京九强生物技术股份有限公司 A kind of enzyme donor conjugate of beta galactosidase and its purposes in glycocholic acid detection
CN106226512B (en) * 2016-07-29 2018-10-16 胡清 A kind of detection method of kit, the preparation method of kit and the peripheral blood glycocholic acid realized using the kit
CN106190996B (en) * 2016-08-30 2019-05-21 美康生物科技股份有限公司 A kind of G 6 PD mutant
CN109609481B (en) * 2016-09-22 2021-02-12 北京九强生物技术股份有限公司 Preparation method of escherichia coli beta galactosidase receptor
CN106872681B (en) * 2017-01-23 2019-11-19 四川精卫食品检测科技有限公司 Amikacin and the two-in-one quick detection enzyme linked immunological kit of kanamycins and its application
CN108593905A (en) * 2017-12-22 2018-09-28 太原瑞盛生物科技有限公司 A kind of digoxin immune detection reagent and its preparation and detection method
CN108586562B (en) * 2018-05-08 2019-09-06 苏州博源医疗科技有限公司 A kind of cortex 01 derivatives and the preparation method and application thereof
CN108717117A (en) * 2018-05-23 2018-10-30 太原瑞盛生物科技有限公司 A kind of vancomycin immunologic function test reagent and its preparation and detection method
CN109111494A (en) * 2018-08-30 2019-01-01 苏州博源医疗科技有限公司 Derivatives of estradiol, immunogene, antibody, enzyme mark conjugate, detection reagent and preparation method thereof
CN110174363A (en) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
CN112574969A (en) * 2020-12-28 2021-03-30 郑州伊美诺生物技术有限公司 G6PDH mutant and application thereof

Also Published As

Publication number Publication date
CN116859035A (en) 2023-10-10
CN116840462A (en) 2023-10-03
CN117030640A (en) 2023-11-10
CN116840468A (en) 2023-10-03
CN111487207B (en) 2023-07-07
CN111693473A (en) 2020-09-22
CN116148198A (en) 2023-05-23
CN116718761A (en) 2023-09-08
CN116626281A (en) 2023-08-22
CN116735512A (en) 2023-09-12
CN116124721A (en) 2023-05-16
CN111504921A (en) 2020-08-07
CN116773827A (en) 2023-09-19
CN112285038A (en) 2021-01-29
CN111487207A (en) 2020-08-04
CN116298330A (en) 2023-06-23
CN111650135A (en) 2020-09-11
CN111678874A (en) 2020-09-18
CN116699125A (en) 2023-09-05
CN116773795A (en) 2023-09-19
CN116144619B (en) 2024-07-12
CN115791649B (en) 2024-10-01
CN111487206B (en) 2023-11-10
CN115791649A (en) 2023-03-14
CN116577495A (en) 2023-08-11
CN111504920B (en) 2023-06-30
CN112285038B (en) 2023-09-19
CN112285037A (en) 2021-01-29
CN117054643A (en) 2023-11-14
CN116577494A (en) 2023-08-11
CN111650135B (en) 2023-05-05
CN116679047A (en) 2023-09-01
CN116297271A (en) 2023-06-23
CN116559472A (en) 2023-08-08
CN111537451A (en) 2020-08-14
CN111693473B (en) 2023-06-16
CN111487208A (en) 2020-08-04
CN111504921B (en) 2023-04-18
CN116699122A (en) 2023-09-05
CN116338215A (en) 2023-06-27
CN116754761A (en) 2023-09-15
CN116144619A (en) 2023-05-23
CN112285037B (en) 2022-11-25
CN111487206A (en) 2020-08-04
CN116430056A (en) 2023-07-14
CN115808398A (en) 2023-03-17
CN116381253A (en) 2023-07-04
CN116298257A (en) 2023-06-23
CN116359146A (en) 2023-06-30
CN111239060A (en) 2020-06-05
CN111678874B (en) 2023-07-14
CN116698772A (en) 2023-09-05
CN116840467A (en) 2023-10-03
CN111537452A (en) 2020-08-14
CN116008201A (en) 2023-04-25
CN116718764A (en) 2023-09-08
CN116819060A (en) 2023-09-29
CN111487208B (en) 2023-07-14
CN117074335A (en) 2023-11-17
CN111537452B (en) 2023-07-04
CN110174363A (en) 2019-08-27
CN111537451B (en) 2023-07-14
CN116355873A (en) 2023-06-30
CN116559425A (en) 2023-08-08
CN111239060B (en) 2023-04-07
CN111504920A (en) 2020-08-07

Similar Documents

Publication Publication Date Title
CN111487208B (en) Glucose 6-phosphate dehydrogenase mutant and application thereof in preparation of methotrexate detection reagent

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination